{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:43:22Z","timestamp":1777178602048,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shionogi & Co., Ltd."},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K08153"],"award-info":[{"award-number":["21K08153"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Global Partnership & X (Cross)- Innovation Initiative, Graduate School of Medicine, Osaka University and Osaka University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tetracyclines exhibit anti-viral, anti-inflammatory, and immunomodulatory activities via various mechanisms. The present study investigated the efficacy and safety of demeclocycline in patients hospitalized with mild-to-moderate COVID-19 via an open-label, multicenter, parallel-group, randomized controlled phase 2 trial. Primary and secondary outcomes included changes from baseline (day 1, before the study treatment) in lymphocytes, cytokines, and SARS-CoV-2 RNA on day 8. Seven, seven, and six patients in the control, demeclocycline 150\u00a0mg daily, and demeclocycline 300\u00a0mg daily groups, respectively, were included in the modified intention-to-treat population that was followed until day 29. A significant change of 191.3\/\u03bcL in the number of CD4<jats:sup>+<\/jats:sup>\u2009T cells from day 1 to day 8 was observed in the demeclocycline 150\u00a0mg group (95% CI 5.1\/\u03bcL\u2013377.6\/\u03bcL) (p\u2009=\u20090.023), whereas that in the control group was 47.8\/\u03bcL (95% CI \u2212\u00a0151.2\/\u03bcL to 246.8\/\u03bcL), which was not significant (p\u2009=\u20090.271). The change rates of CD4<jats:sup>+<\/jats:sup>\u2009T cells negatively correlated with those of IL-6 in the demeclocycline-treated groups (R\u2009=\u2009\u2212\u00a00.807, p\u2009=\u20090.009). All treatment-emergent adverse events were of mild-to-moderate severity. The present results indicate that the treatment of mild-to-moderate COVID-19 patients with demeclocycline elicits immune responses conducive to recovery from COVID-19 with good tolerability.<\/jats:p><jats:p><jats:bold>Trial registration<\/jats:bold>: This study was registered with the Japan Registry of Clinical Trials (Trial registration number: jRCTs051200049; Date of the first registration: 26\/08\/2020).<\/jats:p>","DOI":"10.1038\/s41598-023-41051-2","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T18:02:30Z","timestamp":1692813750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19"],"prefix":"10.1038","volume":"13","author":[{"given":"Kota","family":"Iwahori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Nii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Osa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Goya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"41051_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1 (2021).","journal-title":"Lancet"},{"key":"41051_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201. https:\/\/doi.org\/10.1056\/NEJMoa2101544 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172\u20131183. https:\/\/doi.org\/10.1056\/NEJMoa2107659 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014Final report. N. Engl. J. Med. 383, 1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408. https:\/\/doi.org\/10.1056\/NEJMoa2118542 (2022).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509\u2013520. https:\/\/doi.org\/10.1056\/NEJMoa2116044 (2022).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR9","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941\u20131950. https:\/\/doi.org\/10.1056\/NEJMoa2107934 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR10","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81. https:\/\/doi.org\/10.1056\/NEJMoa2108163 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384, 229\u2013237. https:\/\/doi.org\/10.1056\/NEJMoa2029849 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR12","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","volume":"385","author":"M Dougan","year":"2021","unstructured":"Dougan, M. et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N. Engl. J. Med. 385, 1382\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa2102685 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491\u20131502. https:\/\/doi.org\/10.1056\/NEJMoa2100433 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994 (2021).","journal-title":"N. Engl. J. Med."},{"key":"41051_CR16","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.immuni.2022.08.008","volume":"55","author":"A Bertoletti","year":"2022","unstructured":"Bertoletti, A., Le Bert, N. & Tan, A. T. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity 55, 1764\u20131778. https:\/\/doi.org\/10.1016\/j.immuni.2022.08.008 (2022).","journal-title":"Immunity"},{"key":"41051_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","volume":"26","author":"I Thevarajan","year":"2020","unstructured":"Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19. Nat. Med. 26, 453\u2013455. https:\/\/doi.org\/10.1038\/s41591-020-0819-2 (2020).","journal-title":"Nat. Med."},{"key":"41051_CR18","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","volume":"221","author":"F Wang","year":"2020","unstructured":"Wang, F. et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J. Infect. Dis. 221, 1762\u20131769. https:\/\/doi.org\/10.1093\/infdis\/jiaa150 (2020).","journal-title":"J. Infect. Dis."},{"key":"41051_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/13543784.2022.2054325","volume":"31","author":"J Garrido-Mesa","year":"2022","unstructured":"Garrido-Mesa, J., Adams, K., Galvez, J. & Garrido-Mesa, N. Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: A critical discussion of recent publications. Expert Opin. Investig. Drugs 31, 475\u2013482. https:\/\/doi.org\/10.1080\/13543784.2022.2054325 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"41051_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25215064","author":"M Gendrot","year":"2020","unstructured":"Gendrot, M. et al. In vitro antiviral activity of doxycycline against SARS-CoV-2. Molecules https:\/\/doi.org\/10.3390\/molecules25215064 (2020).","journal-title":"Molecules"},{"key":"41051_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4049\/jimmunol.176.1.567","volume":"176","author":"JC Hoyt","year":"2006","unstructured":"Hoyt, J. C., Ballering, J., Numanami, H., Hayden, J. M. & Robbins, R. A. Doxycycline modulates nitric oxide production in murine lung epithelial cells. J. Immunol. 176, 567\u2013572. https:\/\/doi.org\/10.4049\/jimmunol.176.1.567 (2006).","journal-title":"J. Immunol."},{"key":"41051_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1167\/iovs.04-0929","volume":"46","author":"HS Kim","year":"2005","unstructured":"Kim, H. S., Luo, L., Pflugfelder, S. C. & Li, D. Q. Doxycycline inhibits TGF-beta1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells. Investig. Ophthalmol. Vis. Sci. 46, 840\u2013848. https:\/\/doi.org\/10.1167\/iovs.04-0929 (2005).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"41051_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S2213-2600(21)00310-6","volume":"9","author":"CC Butler","year":"2021","unstructured":"Butler, C. C. et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial. Lancet Respir. Med. 9, 1010\u20131020. https:\/\/doi.org\/10.1016\/S2213-2600(21)00310-6 (2021).","journal-title":"Lancet Respir. Med."},{"key":"41051_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1248\/bpb.b21-00806","volume":"45","author":"Y Noguchi","year":"2022","unstructured":"Noguchi, Y. et al. Tetracyclines enhance anti-tumor T-cell responses induced by a bispecific T-cell engager. Biol. Pharm. Bull. 45, 429\u2013437. https:\/\/doi.org\/10.1248\/bpb.b21-00806 (2022).","journal-title":"Biol. Pharm. Bull."},{"key":"41051_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137155","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. Early and polyantigenic CD4 T cell responses correlate with mild disease in acute COVID-19 donors. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23137155 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"41051_CR26","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728. https:\/\/doi.org\/10.1016\/j.celrep.2021.108728 (2021).","journal-title":"Cell Rep."},{"key":"41051_CR27","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C RydyznskiModerbacher","year":"2020","unstructured":"RydyznskiModerbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996-1012.e1019. https:\/\/doi.org\/10.1016\/j.cell.2020.09.038 (2020).","journal-title":"Cell"},{"key":"41051_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/JLB.4COVA1020-703R","volume":"111","author":"B Belaid","year":"2022","unstructured":"Belaid, B. et al. T cell counts and IL-6 concentration in blood of North African COVID-19 patients are two independent prognostic factors for severe disease and death. J. Leukoc. Biol. 111, 269\u2013281. https:\/\/doi.org\/10.1002\/JLB.4COVA1020-703R (2022).","journal-title":"J. Leukoc. Biol."},{"key":"41051_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827. https:\/\/doi.org\/10.3389\/fimmu.2020.00827 (2020).","journal-title":"Front. Immunol."},{"key":"41051_CR30","doi-asserted-by":"publisher","first-page":"e12421","DOI":"10.15252\/emmm.202012421","volume":"12","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol. Med. 12, e12421. https:\/\/doi.org\/10.15252\/emmm.202012421 (2020).","journal-title":"EMBO Mol. Med."},{"key":"41051_CR31","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S2213-8587(21)00244-8","volume":"9","author":"C Steenblock","year":"2021","unstructured":"Steenblock, C. et al. COVID-19 and metabolic disease: Mechanisms and clinical management. Lancet Diabetes Endocrinol. 9, 786\u2013798. https:\/\/doi.org\/10.1016\/S2213-8587(21)00244-8 (2021).","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41051-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41051-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41051-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T03:14:02Z","timestamp":1700363642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41051-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41051"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-41051-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13809"}}